cyrilzakka/clinical-trials huggingface dataset:
Analysis of Correlation Between Skin Carotenoid Level and Basic Indicators of Health Status Related to Lifestyle in Vietnamese: An Observational Study

To clarify the relationship between vegetable intake and lifestyle-related disease in Vietnam, we measure skin carotenoid levels and basic indicators of health status related to lifestyle and analyze the correlation between them. This is an important study that can lead to dietary suggestions for preventing lifestyle-related diseases in Vietnam.


Eligibility Criteria:
Inclusion Criteria:

1. Adults aged 18 years or older
2. Healthy people or patients with metabolic diseases as obesity, diabetes, hypertension, lipid abnormalities, hyperuricemia
3. People who agreed to participate in the study and be able to complete the Informed Consent Form

Exclusion Criteria:

1. Hospitalized patients
2. Patients with other diseases than metabolic diseases as written in inclusion criteria.
3. People judged to be inappropriate by the principal investigator
The Onset Time of Rocuronium in Emergency and Elective Surgery

Rocuronium, a nondepolarizing neuromuscular blocking agent, is used in general anesthesia to provide conditions for endotracheal intubating. Recommended dose is 0,6 mg/kg and 90 seconds after intravenous injection, patients can be intubated.

Anxiety levels may vary in patients undergoing emergency and elective surgery. Patients undergoing emergency surgery may display exaggerated laryngoscopic responses. The purpose of this study is to investigate the effect of patient anxiety levels on the onset time of rocuronium in terms of anxiety scores and train of four (TOF) 0.1 times.

After obtaining ethics committee approval, American Society of Anesthesiologists physiological status 1 (ASA 1) patients, undergoing elective inguinal hernia repair and acute appendectomy, will be included to trial.

Patients will be taken to the operating room without premedication. Spielberger's State-Trait Anxiety Inventory (STAI) will be administered to patients for determining anxiety level.

Electrocardiogram, blood pressure and peripheric oxygen saturation (SpO2) will be monitored. After opening intravenous access on hand dorsum, ringer lactate solution will be given. Neuromuscular monitoring and drug injections will be done as described in "Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents".

TOF-Guard SX acceleromyograph (Organon-Teknika) will be monitored on corrugator supercilii muscle because of its sensitivity to laryngeal muscles. In induction of anesthesia, propofol 2 mg kg-1 and fentanyl 1 mcg kg-1 will be administered intravenously. After loss of conscious, TOF-Guard SX will be calibrated and then 0.6 mg kg-1 rocuronium will be administered in 5 seconds. 20 milliampere (mA) current TOF stimulation (200 ms, square wave, 2 Hz for 1.5 s) will be repeated in every 15 s. Patients will be intubated in TOF 0.1 time.

STAI score, heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, SpO2, TOF 0.1 time and intubation conditions will be compared between two groups.

Eligibility Criteria:
Inclusion Criteria:

* BMI 18,5-24,9
* ASA 1

Exclusion Criteria:

* Allergy to used drugs during anesthesia
* Neuromuscular disease
* Liver and kidney failure
* Heart failure
* Anticipated difficult airway
* Using aminoglycosides
* BMI\<18,5 and BMI\>25
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients. The safety of this treatment will also be studied.


Eligibility Criteria:
Inclusion Criteria:

* Men and women ≥18 years diagnosed with Chronic Phase Philadelphia chromosome positive (CP Ph+) CML who have failed to achieve CCyR after 3-18 months of therapy with imatinib 400 mg
* Treatment initiation with imatinib 400 mg within 6 months of initial CML diagnosis
* Able to tolerate chronic administration of imatinib at the highest dose (400-600 mg) the subject has received in the past
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
* Adequate hepatic and renal function

Exclusion Criteria:

* Eligible and willing to undergo immediate autologous/allogeneic stem cell transplant
* Previous diagnosis of accelerated/blast crisis CML
* Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases
* Previous documentation of T315I mutation
* Uncontrolled or significant cardiovascular disease
* Serious uncontrolled medical disorder/active infection
* History of significant bleeding disorder unrelated to CML
* Intolerance to imatinib ≥400 mg
* Concurrent malignancies other than CML
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke

The intent of this clinical study is to answer the questions:

1. Is the proposed treatment safe
2. Is treatment effective in improving the disease pathology of patients after Stroke and clinical outcomes?

Adipose-Derived Stromal Cells (ASCs) are a novel therapy for patients suffering from stroke. By injecting ASCs either into the internal carotid artery, these regions may become populated with the ASCs, thereby potentially restoring brain function. ASCs are a patient-derived ("autologous") cell transplantation technology that is delivered to the patient into the internal carotid artery and intravenously. The therapy is composed of cells derived from a patients' own adipose tissue that are isolated within approximately 1 hour and immediately delivered back to the patient.

Eligibility Criteria:
Inclusion Criteria:

* Males and Females between Age 18 and 80 years.
* Symptoms and signs of clinically definite ischemic stroke or hemorrhagic stroke
* DWI-MRI has reliably shown relevant ischemic lesions
* Extracranial duplex/transcranial Doppler must confirm intra/extracranial arteries permeability
* The stroke is severe (NIH Stroke Scale \>= 8 before procedure)
* Up to date on all age and gender appropriate cancer screening per American Cancer Society.

Exclusion Criteria:

* Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
* Life expectancy \< 6 months due to concomitant illnesses.
* Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
* Active infectious disease and/or known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM \> IgG) and/or syphilis will have expert consultation to determine eligibility based on the patient's infectious status
* Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
* Patients on chronic immunosuppressive transplant therapy
* Systolic blood pressure (supine) ≤90 mmHg or greater than 180mmHg
* Resting heart rate \> 100 bpm;
* Active clinical infection being treated by antibiotics within one week of enrollment.
* Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
* History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
* Unwilling and/or not able to give written informed consent.
Population-based Registry Study on Primary Hip Fracture Surgery

This study aims to describe primary hip fracture surgeries and to identify patient-related and perioperative risk factors affecting outcomes. It will utilize data from the Swedish Perioperative Registry (SPOR) and the Swedish National Patient Register to track epidemiological changes, treatment outcomes, and perioperative factors.

Hip fractures, a significant health concern among the elderly, necessitate hospitalization and surgical intervention, with high mortality and morbidity rates within the first year post-surgery. The study will retrospectively analyze records of approximately 90,000 patients over 18 who underwent hip fracture surgery between 2018 and 2022. Key factors such as age, sex, preoperative health status, and perioperative care methods will be evaluated to determine their impact on complications, reoperation rates, and survival.

This research could inform future clinical practices and policies, aiming to optimize the treatment and management of elderly patients with hip fractures.

Eligibility Criteria:
Inclusion Criteria:

- Patients aged 18+ with hip fractures, identified through ICD code S72\*, who underwent surgery during the study period.

Exclusion Criteria:

* Patients without a Swedish personal identification number, as this is necessary to link data across registers.
JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls

The purpose of this study is to have girls play new computer games designed for middle school children and not yet available to the public. The investigator wants to know what girls think about these games. The investigator also wants to learn about the health behavior of 7th grade girls of Hispanic/Brazilian/Latino origin, and the investigators want to test the Mighty Girls program in Miami. Half of the girls in JUEGA will be given the Mighty Girls program and the investigators want to know if this program reduces behavior that puts girls at risk for having sex, drinking, and using drugs. The program tries to reduce this risk by helping girls learn skills to make wise choices, even when their friends have other ideas or want them to make more risky choices This goal is important because US statistics indicate that Hispanic teens are at risk for teen pregnancy and Miami has one of the highest HIV and AIDS rates in the United States. The investigator wants to find out whether the Mighty Girls program is as effective in Miami-Dade County Public Schools as it was when tested in one of Orlando's Orange County Public Schools.


Eligibility Criteria:
Inclusion Criteria:

* English Speaking
* enrolled in 7th grade at a participating school

Exclusion Criteria:

* developmental delay
Mammography and Breast Arterial Calcification: an Information-Sharing Trial

The purpose of this research study is to determine the potential benefits of adding information on patients' breast arterial calcification (BAC) results to the standard results letter women receive after mammography. In addition to looking for potential breast cancer, research shows that mammograms can also detect the presence of calcifications within the breast arteries. Those calcifications can be associated with coronary artery disease. Right now, women are not routinely told whether or not they have BAC; that is, it's not part of standard practice to communicate that information to patients. However, previous research has suggested that patients would like to be informed about their BAC status more often. In this study, the team has two goals. First, the team wants to measure the rates of BAC in a large, diverse group of 14,875 women. Because most of the past research on BAC has largely been focused on White mammography patients, the researchers feel it is important to see if the results are similar or different in a more racially and ethnically diverse sample.

Second, the study team wants to understand the effects of giving women information on their BAC results as part of their standard post-mammography letter. Specifically, the study team wants to see how sharing that information might affect women's healthcare choices and lifestyle. The research will include 1,888 women in this second part of the study, which will be the first in the literature to explore women's reactions to BAC information. If research shows that women find the information useful, BAC information may be given to women regularly in the future.


Eligibility Criteria:
Inclusion Criteria

* Female
* Scheduled to undergo mammography at one of Mount Sinai's breast radiology clinics (e.g., Dubin Breast Center, Radiology Associates)
* Age ≥ 40 years
* Read and speak English or Spanish
* Ability to understand and the willingness to sign a written informed consent
* Willing to sign and date any applicable medical record release documents for the study

Exclusion Criteria:

* Participants with known coronary artery disease (via self-report)
* Previous physician-diagnosed heart attack, stroke or TIA, heart failure, angina or taking nitroglycerin, or atrial fibrillation (via self-report or review of EMR)
* Inability to understand and comply with the instructions of the study due to the presence of cognitive or psychiatric conditions (such as dementia, psychosis, or mania), compromising ability to provide informed consent and/or follow study procedures
* Pregnant women
Hybrid PET/MR in the Therapy of Cervical Cancer

This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals. Subjects will undergo PET/MRI scans before, during (chemoradiation group only), and after treatment.

The primary purpose of this study is to evaluate the feasibility of obtaining complete and interpretable hybrid PET/MR images for patients diagnosed with cervical cancer.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years of age
* Biopsy-proven, previously untreated squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix
* Clinically visible lesion at least FIGO stage Ib or AJCC 7th edition T1b
* Scheduled to undergo standard of care PET/CT for baseline assessment of disease
* Anticipated to be eligible for curative intent therapy (surgery of chemoradiation therapy) as determined by the patient's primary oncologist
* If female of child-bearing potential, negative serum or urine pregnancy test ≤ 7 dats prior to first PET/MRI
* Informed consent reviewed and signed

Exclusion Criteria:

* History of sever reaction to contrast-enhanced CT scan
* Inability to tolerate MRI (e.g., inability to lie flat \> 1 hour)
* Presence of pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes
* Poorly controlled diabetes mellitus
* Creatinine \> 1.4 mg/dL or GFR \< 30 mL/min
* Body Mass Index (BMI) \> 35
* Active vaginal bleeding requiring packing and emergent radiation therapy
* Pregnant or lactating female
* History of a prior malignancy within past 5 years, unless disease free for ≥ 3 years
* Substance abuse, medical, psychological, or social conditions that may interfere with study participation
Preliminary Efficacy of a Technology-based Physical Activity Intervention for Older Korean Adults During the COVID-19 Pandemic

This study tested preliminary efficacy of a hybrid (web-based and center-based) PA intervention combining use of a smartwatch and mobile application. The 12-week hybrid PA intervention included 120 older Korean adults and was concurrently implemented in-person at the local senior center and at-home through a web-based modality. Overall, increases were evident in systolic/diastolic blood pressure, total cholesterol, and high-density-lipoprotein at posttest, with decreases seen for triglyceride levels. Participants showed improvements in muscular function and cardiopulmonary endurance.


Eligibility Criteria:
Inclusion Criteria:

* aged 60 and over
* enrolled member at the participating senior center for at least three years
* fluent in Korean

Exclusion Criteria:

* younger than 60 years old
* less than three years enrollment at the senior center
* cannot read and speak Korean
Feasibility Trial of a Single Session of Crisis Response Planning for Youth at High Risk for Suicide

The current study is a clinical trial, meaning a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related behavioral outcomes. Specifically, male and female adolescents with current suicidal intent will be randomly assigned to receive either a 1-hour session of virtual crisis response planning (CRP), a 1-hour session of in-person CRP, or a 1-hour session of standard crisis risk management (treatment as usual). The feasibility and acceptability of the virtual CRP, compared to in-person CRP, will be assessed 14 days post-treatment. Additional assessments of changes in mood, behavior, and suicidality will be collected daily for 14 days post-treatment via ecological momentary assessments. The investigators hypothesize the following: 1) Virtual CRP will be rated as more feasible and acceptable compared to traditional CRP and treatment as usual interventions; 2) Both versions of CRP will be associated with changes in frequency and severity of suicidal ideation and behavior compared to treatment as usual; 3) Virtual CRP will be equally as effective as traditional CRP at reducing suicide risk, suggesting that virtual CRP is a promising scalable intervention adaptation.


Eligibility Criteria:
Inclusion Criteria:

* Participant is 14-18 years old at the time of assent/consent
* Participant's legal guardian is willing and able to give parental permission (if 14-17 years old)
* Participant is able to give informed assent or consent (as applicable by age)
* Participant endorses current desires to make a suicide attempt as defined as answering "yes" to item #3 on the Ask Suicide Screening Question (ASQ) tool

Exclusion Criteria:

* Factors that would interfere with data interpretation including serious medical or neurologic conditions
* Presence of current moderate to severe substance use disorder
* Lack of access to a personal smartphone
* Lack of fluency in English
Arginine Synthesis in Healthy Adult Humans

Arginine synthesis in mammals is a complex process involving at least 8 enzymes and intracellular and interorgan transfer of substrates.

The investigators have shown in our neonatal studies that there is no conversion of glutamate to arginine but proline label appears in ornithine, citrulline and arginine. It is clear therefore that arginine is synthesized in human neonates from proline.

In adults the source of the carbon backbone is less clear.

Through a series of test in healthy adults using tandem mass spectrometry with carbon labeled GLN and nitrogen labeled PRO to determine the dietary source for the carbon chain of ORN, CIT and ARG. Additionally, using Nitrogen labeled GLN, we will identify the source of the nitrogen atoms in these amino acids.

Using guanidino - 15N2 arginine, 1-13C Glutamine, 2-15N Glutamine and 15N Proline we will be able to:

1. determine the flux of arginine and proline in healthy adult volunteers
2. determine and compare the flux of carbon and nitrogen labeled glutamine
3. demonstrate whether glutamine or proline provides the carbon backbone for ornithine, citrulline and arginine in adults.
4. the source of the N atoms in ornithine, citrulline and arginine.

Eligibility Criteria:
Inclusion Criteria:

* 5 men of average weight 80 kg will be studied
* healthy, with no know disease of liver, and/or kidney
* weight stable

Exclusion Criteria:

* weith loss or gain over the last three months
* on medications known to affect amino acid metabolism
* known liver, kidney disease condition
Study on the Device "Gondola" for Motor Rehabilitation in Parkinson's Disease

The purpose of this research study is to evaluate safety and effectiveness of the Automated Mechanical Peripheral Stimulation (AMPS) therapy given via the Gondola™ device to improving Gait and Gait Related Disorders in patients with Parkinson'disease (PD). Gondola® is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the therapy requires less than 2 minutes.

The proposed project, through a randomized multicentric, placebo controlled double-blind crossover trial aimed at evaluating the effectiveness of AMPS Gondola therapy versus Sham Gondola therapy in PD subjects. 132 in/outpatients with PD will be recruited. Subjects will be randomized in 2 groups, one starting with AMPS treatment, the other with placebo treatment. At the end of the first cycle of 6 stimulations over a 3 weeks' time (AMPS or Sham), all subjects will undergo a washout period of minimum 6 weeks, then will undergo another equivalent treatment cycle (Sham or AMPS); a follow up valuation 14 days after the end of each treatment cycle will be performed.

This project is aimed at studying and documenting the effects of the AMPS treatment given to PD patients via the Gondola device in:

1. Improving gait, reducing bradykinesia, treating Freezing of Gait symptom;
2. Improving UPDRS II and III scores;
3. Improving balance. Another goal of the study is to document the safety of the Gondola device.

Eligibility Criteria:
Inclusion criteria:

* Patients with clinically chronic and stable PD, confirmed according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBC);
* Age 45 and older;
* Hoehn \& Yahr (H\&Y) stage equal or higher than 2 in ON state;
* Ability to walk autonomously or with minimal assistance for a 10 meters' distance in OFF state;
* Antiparkinsonian treatment at a stable and optimized daily dosage during the 4 weeks prior to the study.

Exclusion criteria

* Any advanced, severe or unstable disease other than PD, which may interfere with the primary and secondary study outcome evaluations (autonomic dysfunction, diabetes, renal or hepatic failure, neoplasia, balance and gait problems of other origin).
* Cognitive impairment with MoCA \< 18
* Any peripheral neurological or musculoskeletal conditions that may alter balance and/or gait.
* Severe lower limb injuries in the previous 6 months.
* History of neurosurgery or orthopedic surgery.
* History of epilepsy.
* Any drug treatment not intended to treat PD that may alter cognitive and/or motor performance.
* History of depression or other psychiatric disorders.
* Severe obesity defined as a BMI greater than 35.
Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients

The purpose of the study is to evaluate the effect of real-time continuous glucose monitoring system on glucose control and outcomes of critically ill patients.

Real-time continuous glucose monitoring system has shown great accuracy and feasibility in critically ill patients. However, its impact on glucose control and outcomes has nearly unknown. Thus, Investigators designed this study to evaluate the effect of real-time continuous glucose monitoring system on glucose control and outcomes of critically ill patients.

Eligibility Criteria:
Inclusion Criteria:

* More than 18 years old male or female;

  * Expected ICU stays longer than 72 hours;

    * Glucose level more than 8 mmol/L when enrolls in the ICU;

      * Patients or their legal surrogates have signed the informed consent.

Exclusion Criteria:

* Pregnant or lactating women;

  * ICU stays less than 72 hours;

    * Usage of real-time continuous glucose monitoring system is considered as a contraindication.